nodes	percent_of_prediction	percent_of_DWPC	metapath
Imiquimod—skin cancer—bone cancer	0.665	1	CtDrD
Imiquimod—CYP3A4—bone cancer	0.263	1	CbGaD
Imiquimod—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.00104	0.0808	CbGpPWpGaD
Imiquimod—TLR8—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—ATF1—bone cancer	0.000686	0.0536	CbGpPWpGaD
Imiquimod—TLR8—MyD88 dependent cascade initiated on endosome—ATF1—bone cancer	0.000674	0.0526	CbGpPWpGaD
Imiquimod—TLR8—Toll Like Receptor 9 (TLR9) Cascade—ATF1—bone cancer	0.00065	0.0507	CbGpPWpGaD
Imiquimod—TLR7—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—ATF1—bone cancer	0.00052	0.0406	CbGpPWpGaD
Imiquimod—TLR7—MyD88 dependent cascade initiated on endosome—ATF1—bone cancer	0.000511	0.0399	CbGpPWpGaD
Imiquimod—TLR7—Toll Like Receptor 9 (TLR9) Cascade—ATF1—bone cancer	0.000493	0.0385	CbGpPWpGaD
Imiquimod—TLR8—Toll-Like Receptors Cascades—ATF1—bone cancer	0.000462	0.0361	CbGpPWpGaD
Imiquimod—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.00038	0.0297	CbGpPWpGaD
Imiquimod—TLR7—Toll-Like Receptors Cascades—ATF1—bone cancer	0.00035	0.0273	CbGpPWpGaD
Imiquimod—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00034	0.0265	CbGpPWpGaD
Imiquimod—TLR8—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—JUN—bone cancer	0.000267	0.0209	CbGpPWpGaD
Imiquimod—TLR8—MyD88 dependent cascade initiated on endosome—JUN—bone cancer	0.000263	0.0205	CbGpPWpGaD
Imiquimod—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000263	0.0205	CbGpPWpGaD
Imiquimod—TLR8—Toll Like Receptor 9 (TLR9) Cascade—JUN—bone cancer	0.000253	0.0198	CbGpPWpGaD
Imiquimod—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000247	0.0193	CbGpPWpGaD
Imiquimod—TLR8—Toll-like Receptor Signaling Pathway—JUN—bone cancer	0.000233	0.0182	CbGpPWpGaD
Imiquimod—TLR7—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—JUN—bone cancer	0.000203	0.0158	CbGpPWpGaD
Imiquimod—TLR7—MyD88 dependent cascade initiated on endosome—JUN—bone cancer	0.000199	0.0155	CbGpPWpGaD
Imiquimod—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000196	0.0153	CbGpPWpGaD
Imiquimod—TLR7—Toll Like Receptor 9 (TLR9) Cascade—JUN—bone cancer	0.000192	0.015	CbGpPWpGaD
Imiquimod—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000184	0.0143	CbGpPWpGaD
Imiquimod—TLR8—Regulation of toll-like receptor signaling pathway—JUN—bone cancer	0.000182	0.0142	CbGpPWpGaD
Imiquimod—TLR8—Toll-Like Receptors Cascades—JUN—bone cancer	0.00018	0.0141	CbGpPWpGaD
Imiquimod—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000179	0.0139	CbGpPWpGaD
Imiquimod—TLR7—Toll-like Receptor Signaling Pathway—JUN—bone cancer	0.000177	0.0138	CbGpPWpGaD
Imiquimod—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000171	0.0133	CbGpPWpGaD
Imiquimod—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000164	0.0128	CbGpPWpGaD
Imiquimod—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000158	0.0123	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—ATF1—bone cancer	0.00015	0.0117	CbGpPWpGaD
Imiquimod—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000146	0.0114	CbGpPWpGaD
Imiquimod—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000142	0.0111	CbGpPWpGaD
Imiquimod—TLR7—Regulation of toll-like receptor signaling pathway—JUN—bone cancer	0.000138	0.0108	CbGpPWpGaD
Imiquimod—TLR7—Toll-Like Receptors Cascades—JUN—bone cancer	0.000136	0.0106	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—ATF1—bone cancer	0.000113	0.00885	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000113	0.00882	CbGpPWpGaD
Imiquimod—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000107	0.00838	CbGpPWpGaD
Imiquimod—Paraesthesia—Cisplatin—bone cancer	0.000106	0.00178	CcSEcCtD
Imiquimod—Upper respiratory tract infection—Methotrexate—bone cancer	0.000106	0.00178	CcSEcCtD
Imiquimod—Dyspnoea—Cisplatin—bone cancer	0.000105	0.00177	CcSEcCtD
Imiquimod—Erectile dysfunction—Methotrexate—bone cancer	0.000105	0.00176	CcSEcCtD
Imiquimod—Photosensitivity reaction—Methotrexate—bone cancer	0.000104	0.00174	CcSEcCtD
Imiquimod—Breast disorder—Doxorubicin—bone cancer	0.000103	0.00173	CcSEcCtD
Imiquimod—Decreased appetite—Cisplatin—bone cancer	0.000102	0.00172	CcSEcCtD
Imiquimod—Bronchitis—Epirubicin—bone cancer	0.000102	0.00172	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Cisplatin—bone cancer	0.000102	0.00171	CcSEcCtD
Imiquimod—Infestation NOS—Methotrexate—bone cancer	0.000101	0.0017	CcSEcCtD
Imiquimod—Infestation—Methotrexate—bone cancer	0.000101	0.0017	CcSEcCtD
Imiquimod—Depression—Methotrexate—bone cancer	0.000101	0.0017	CcSEcCtD
Imiquimod—Pancytopenia—Epirubicin—bone cancer	0.000101	0.0017	CcSEcCtD
Imiquimod—Pain—Cisplatin—bone cancer	0.000101	0.00169	CcSEcCtD
Imiquimod—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000101	0.00169	CcSEcCtD
Imiquimod—Dysuria—Epirubicin—bone cancer	9.95e-05	0.00167	CcSEcCtD
Imiquimod—Upper respiratory tract infection—Epirubicin—bone cancer	9.89e-05	0.00166	CcSEcCtD
Imiquimod—Conjunctivitis—Methotrexate—bone cancer	9.86e-05	0.00166	CcSEcCtD
Imiquimod—Influenza—Doxorubicin—bone cancer	9.85e-05	0.00165	CcSEcCtD
Imiquimod—Photosensitivity reaction—Epirubicin—bone cancer	9.72e-05	0.00163	CcSEcCtD
Imiquimod—Feeling abnormal—Cisplatin—bone cancer	9.71e-05	0.00163	CcSEcCtD
Imiquimod—Hepatobiliary disease—Methotrexate—bone cancer	9.59e-05	0.00161	CcSEcCtD
Imiquimod—Infestation NOS—Epirubicin—bone cancer	9.49e-05	0.00159	CcSEcCtD
Imiquimod—Infestation—Epirubicin—bone cancer	9.49e-05	0.00159	CcSEcCtD
Imiquimod—Bronchitis—Doxorubicin—bone cancer	9.47e-05	0.00159	CcSEcCtD
Imiquimod—Stevens-Johnson syndrome—Epirubicin—bone cancer	9.41e-05	0.00158	CcSEcCtD
Imiquimod—Pancytopenia—Doxorubicin—bone cancer	9.35e-05	0.00157	CcSEcCtD
Imiquimod—Body temperature increased—Cisplatin—bone cancer	9.32e-05	0.00157	CcSEcCtD
Imiquimod—Neuropathy peripheral—Epirubicin—bone cancer	9.3e-05	0.00156	CcSEcCtD
Imiquimod—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	9.26e-05	0.00722	CbGpPWpGaD
Imiquimod—Urinary tract infection—Epirubicin—bone cancer	9.22e-05	0.00155	CcSEcCtD
Imiquimod—Conjunctivitis—Epirubicin—bone cancer	9.22e-05	0.00155	CcSEcCtD
Imiquimod—Dysuria—Doxorubicin—bone cancer	9.21e-05	0.00155	CcSEcCtD
Imiquimod—Upper respiratory tract infection—Doxorubicin—bone cancer	9.15e-05	0.00154	CcSEcCtD
Imiquimod—Haemoglobin—Methotrexate—bone cancer	9.15e-05	0.00154	CcSEcCtD
Imiquimod—Haemorrhage—Methotrexate—bone cancer	9.1e-05	0.00153	CcSEcCtD
Imiquimod—Pharyngitis—Methotrexate—bone cancer	9.04e-05	0.00152	CcSEcCtD
Imiquimod—Urinary tract disorder—Methotrexate—bone cancer	8.99e-05	0.00151	CcSEcCtD
Imiquimod—Photosensitivity reaction—Doxorubicin—bone cancer	8.99e-05	0.00151	CcSEcCtD
Imiquimod—Hepatobiliary disease—Epirubicin—bone cancer	8.98e-05	0.00151	CcSEcCtD
Imiquimod—Urethral disorder—Methotrexate—bone cancer	8.92e-05	0.0015	CcSEcCtD
Imiquimod—Sinusitis—Epirubicin—bone cancer	8.9e-05	0.0015	CcSEcCtD
Imiquimod—Infestation—Doxorubicin—bone cancer	8.78e-05	0.00148	CcSEcCtD
Imiquimod—Infestation NOS—Doxorubicin—bone cancer	8.78e-05	0.00148	CcSEcCtD
Imiquimod—Visual impairment—Methotrexate—bone cancer	8.77e-05	0.00147	CcSEcCtD
Imiquimod—TLR8—Immune System—ATF1—bone cancer	8.72e-05	0.0068	CbGpPWpGaD
Imiquimod—Stevens-Johnson syndrome—Doxorubicin—bone cancer	8.71e-05	0.00146	CcSEcCtD
Imiquimod—Hypersensitivity—Cisplatin—bone cancer	8.68e-05	0.00146	CcSEcCtD
Imiquimod—Erythema multiforme—Methotrexate—bone cancer	8.61e-05	0.00145	CcSEcCtD
Imiquimod—Neuropathy peripheral—Doxorubicin—bone cancer	8.61e-05	0.00145	CcSEcCtD
Imiquimod—Haemoglobin—Epirubicin—bone cancer	8.56e-05	0.00144	CcSEcCtD
Imiquimod—Rhinitis—Epirubicin—bone cancer	8.54e-05	0.00143	CcSEcCtD
Imiquimod—Urinary tract infection—Doxorubicin—bone cancer	8.54e-05	0.00143	CcSEcCtD
Imiquimod—Conjunctivitis—Doxorubicin—bone cancer	8.54e-05	0.00143	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—KIT—bone cancer	8.52e-05	0.00665	CbGpPWpGaD
Imiquimod—Haemorrhage—Epirubicin—bone cancer	8.52e-05	0.00143	CcSEcCtD
Imiquimod—Eye disorder—Methotrexate—bone cancer	8.51e-05	0.00143	CcSEcCtD
Imiquimod—TLR8—Immune System—IL3—bone cancer	8.5e-05	0.00664	CbGpPWpGaD
Imiquimod—Tinnitus—Methotrexate—bone cancer	8.49e-05	0.00143	CcSEcCtD
Imiquimod—Asthenia—Cisplatin—bone cancer	8.46e-05	0.00142	CcSEcCtD
Imiquimod—Pharyngitis—Epirubicin—bone cancer	8.46e-05	0.00142	CcSEcCtD
Imiquimod—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	8.43e-05	0.00658	CbGpPWpGaD
Imiquimod—Urinary tract disorder—Epirubicin—bone cancer	8.41e-05	0.00141	CcSEcCtD
Imiquimod—Connective tissue disorder—Epirubicin—bone cancer	8.37e-05	0.00141	CcSEcCtD
Imiquimod—Urethral disorder—Epirubicin—bone cancer	8.35e-05	0.0014	CcSEcCtD
Imiquimod—Hepatobiliary disease—Doxorubicin—bone cancer	8.3e-05	0.0014	CcSEcCtD
Imiquimod—Angiopathy—Methotrexate—bone cancer	8.26e-05	0.00139	CcSEcCtD
Imiquimod—Sinusitis—Doxorubicin—bone cancer	8.24e-05	0.00138	CcSEcCtD
Imiquimod—Immune system disorder—Methotrexate—bone cancer	8.22e-05	0.00138	CcSEcCtD
Imiquimod—Visual impairment—Epirubicin—bone cancer	8.21e-05	0.00138	CcSEcCtD
Imiquimod—Mediastinal disorder—Methotrexate—bone cancer	8.2e-05	0.00138	CcSEcCtD
Imiquimod—Chills—Methotrexate—bone cancer	8.17e-05	0.00137	CcSEcCtD
Imiquimod—Diarrhoea—Cisplatin—bone cancer	8.06e-05	0.00135	CcSEcCtD
Imiquimod—Erythema multiforme—Epirubicin—bone cancer	8.06e-05	0.00135	CcSEcCtD
Imiquimod—Alopecia—Methotrexate—bone cancer	8.04e-05	0.00135	CcSEcCtD
Imiquimod—Mental disorder—Methotrexate—bone cancer	7.98e-05	0.00134	CcSEcCtD
Imiquimod—Eye disorder—Epirubicin—bone cancer	7.96e-05	0.00134	CcSEcCtD
Imiquimod—Tinnitus—Epirubicin—bone cancer	7.94e-05	0.00133	CcSEcCtD
Imiquimod—Malnutrition—Methotrexate—bone cancer	7.92e-05	0.00133	CcSEcCtD
Imiquimod—Erythema—Methotrexate—bone cancer	7.92e-05	0.00133	CcSEcCtD
Imiquimod—Haemoglobin—Doxorubicin—bone cancer	7.92e-05	0.00133	CcSEcCtD
Imiquimod—Flushing—Epirubicin—bone cancer	7.91e-05	0.00133	CcSEcCtD
Imiquimod—Rhinitis—Doxorubicin—bone cancer	7.9e-05	0.00133	CcSEcCtD
Imiquimod—Haemorrhage—Doxorubicin—bone cancer	7.88e-05	0.00132	CcSEcCtD
Imiquimod—Pharyngitis—Doxorubicin—bone cancer	7.82e-05	0.00131	CcSEcCtD
Imiquimod—Urinary tract disorder—Doxorubicin—bone cancer	7.78e-05	0.00131	CcSEcCtD
Imiquimod—Connective tissue disorder—Doxorubicin—bone cancer	7.75e-05	0.0013	CcSEcCtD
Imiquimod—Angiopathy—Epirubicin—bone cancer	7.73e-05	0.0013	CcSEcCtD
Imiquimod—Urethral disorder—Doxorubicin—bone cancer	7.73e-05	0.0013	CcSEcCtD
Imiquimod—Immune system disorder—Epirubicin—bone cancer	7.7e-05	0.00129	CcSEcCtD
Imiquimod—Mediastinal disorder—Epirubicin—bone cancer	7.68e-05	0.00129	CcSEcCtD
Imiquimod—Back pain—Methotrexate—bone cancer	7.67e-05	0.00129	CcSEcCtD
Imiquimod—Chills—Epirubicin—bone cancer	7.64e-05	0.00128	CcSEcCtD
Imiquimod—Arrhythmia—Epirubicin—bone cancer	7.61e-05	0.00128	CcSEcCtD
Imiquimod—Visual impairment—Doxorubicin—bone cancer	7.6e-05	0.00128	CcSEcCtD
Imiquimod—Alopecia—Epirubicin—bone cancer	7.53e-05	0.00126	CcSEcCtD
Imiquimod—Vomiting—Cisplatin—bone cancer	7.49e-05	0.00126	CcSEcCtD
Imiquimod—Mental disorder—Epirubicin—bone cancer	7.46e-05	0.00125	CcSEcCtD
Imiquimod—Erythema multiforme—Doxorubicin—bone cancer	7.45e-05	0.00125	CcSEcCtD
Imiquimod—Rash—Cisplatin—bone cancer	7.43e-05	0.00125	CcSEcCtD
Imiquimod—Dermatitis—Cisplatin—bone cancer	7.42e-05	0.00125	CcSEcCtD
Imiquimod—Malnutrition—Epirubicin—bone cancer	7.42e-05	0.00125	CcSEcCtD
Imiquimod—Erythema—Epirubicin—bone cancer	7.42e-05	0.00125	CcSEcCtD
Imiquimod—Eye disorder—Doxorubicin—bone cancer	7.37e-05	0.00124	CcSEcCtD
Imiquimod—Ill-defined disorder—Methotrexate—bone cancer	7.35e-05	0.00124	CcSEcCtD
Imiquimod—Tinnitus—Doxorubicin—bone cancer	7.35e-05	0.00123	CcSEcCtD
Imiquimod—Flushing—Doxorubicin—bone cancer	7.32e-05	0.00123	CcSEcCtD
Imiquimod—Back pain—Epirubicin—bone cancer	7.17e-05	0.00121	CcSEcCtD
Imiquimod—Angiopathy—Doxorubicin—bone cancer	7.15e-05	0.0012	CcSEcCtD
Imiquimod—Malaise—Methotrexate—bone cancer	7.15e-05	0.0012	CcSEcCtD
Imiquimod—Immune system disorder—Doxorubicin—bone cancer	7.12e-05	0.0012	CcSEcCtD
Imiquimod—Mediastinal disorder—Doxorubicin—bone cancer	7.1e-05	0.00119	CcSEcCtD
Imiquimod—Chills—Doxorubicin—bone cancer	7.07e-05	0.00119	CcSEcCtD
Imiquimod—Arrhythmia—Doxorubicin—bone cancer	7.04e-05	0.00118	CcSEcCtD
Imiquimod—Nausea—Cisplatin—bone cancer	7e-05	0.00118	CcSEcCtD
Imiquimod—Alopecia—Doxorubicin—bone cancer	6.97e-05	0.00117	CcSEcCtD
Imiquimod—Cough—Methotrexate—bone cancer	6.92e-05	0.00116	CcSEcCtD
Imiquimod—Mental disorder—Doxorubicin—bone cancer	6.91e-05	0.00116	CcSEcCtD
Imiquimod—Ill-defined disorder—Epirubicin—bone cancer	6.88e-05	0.00116	CcSEcCtD
Imiquimod—Convulsion—Methotrexate—bone cancer	6.87e-05	0.00115	CcSEcCtD
Imiquimod—Malnutrition—Doxorubicin—bone cancer	6.86e-05	0.00115	CcSEcCtD
Imiquimod—Erythema—Doxorubicin—bone cancer	6.86e-05	0.00115	CcSEcCtD
Imiquimod—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	6.82e-05	0.00532	CbGpPWpGaD
Imiquimod—Agitation—Epirubicin—bone cancer	6.82e-05	0.00114	CcSEcCtD
Imiquimod—Chest pain—Methotrexate—bone cancer	6.75e-05	0.00113	CcSEcCtD
Imiquimod—Myalgia—Methotrexate—bone cancer	6.75e-05	0.00113	CcSEcCtD
Imiquimod—Arthralgia—Methotrexate—bone cancer	6.75e-05	0.00113	CcSEcCtD
Imiquimod—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	6.73e-05	0.00525	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—MDM2—bone cancer	6.71e-05	0.00524	CbGpPWpGaD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	6.7e-05	0.00113	CcSEcCtD
Imiquimod—Malaise—Epirubicin—bone cancer	6.69e-05	0.00112	CcSEcCtD
Imiquimod—Discomfort—Methotrexate—bone cancer	6.67e-05	0.00112	CcSEcCtD
Imiquimod—Syncope—Epirubicin—bone cancer	6.65e-05	0.00112	CcSEcCtD
Imiquimod—Back pain—Doxorubicin—bone cancer	6.64e-05	0.00112	CcSEcCtD
Imiquimod—TLR7—Immune System—ATF1—bone cancer	6.61e-05	0.00516	CbGpPWpGaD
Imiquimod—Palpitations—Epirubicin—bone cancer	6.55e-05	0.0011	CcSEcCtD
Imiquimod—Loss of consciousness—Epirubicin—bone cancer	6.52e-05	0.0011	CcSEcCtD
Imiquimod—Cough—Epirubicin—bone cancer	6.47e-05	0.00109	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—KIT—bone cancer	6.46e-05	0.00504	CbGpPWpGaD
Imiquimod—TLR7—Immune System—IL3—bone cancer	6.44e-05	0.00503	CbGpPWpGaD
Imiquimod—Convulsion—Epirubicin—bone cancer	6.43e-05	0.00108	CcSEcCtD
Imiquimod—Infection—Methotrexate—bone cancer	6.43e-05	0.00108	CcSEcCtD
Imiquimod—Hypertension—Epirubicin—bone cancer	6.4e-05	0.00108	CcSEcCtD
Imiquimod—Ill-defined disorder—Doxorubicin—bone cancer	6.37e-05	0.00107	CcSEcCtD
Imiquimod—Nervous system disorder—Methotrexate—bone cancer	6.34e-05	0.00107	CcSEcCtD
Imiquimod—Chest pain—Epirubicin—bone cancer	6.31e-05	0.00106	CcSEcCtD
Imiquimod—Arthralgia—Epirubicin—bone cancer	6.31e-05	0.00106	CcSEcCtD
Imiquimod—Myalgia—Epirubicin—bone cancer	6.31e-05	0.00106	CcSEcCtD
Imiquimod—Agitation—Doxorubicin—bone cancer	6.31e-05	0.00106	CcSEcCtD
Imiquimod—Anxiety—Epirubicin—bone cancer	6.29e-05	0.00106	CcSEcCtD
Imiquimod—Skin disorder—Methotrexate—bone cancer	6.28e-05	0.00106	CcSEcCtD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	6.27e-05	0.00105	CcSEcCtD
Imiquimod—Hyperhidrosis—Methotrexate—bone cancer	6.25e-05	0.00105	CcSEcCtD
Imiquimod—Discomfort—Epirubicin—bone cancer	6.24e-05	0.00105	CcSEcCtD
Imiquimod—Malaise—Doxorubicin—bone cancer	6.19e-05	0.00104	CcSEcCtD
Imiquimod—Dry mouth—Epirubicin—bone cancer	6.17e-05	0.00104	CcSEcCtD
Imiquimod—Anorexia—Methotrexate—bone cancer	6.17e-05	0.00104	CcSEcCtD
Imiquimod—Syncope—Doxorubicin—bone cancer	6.15e-05	0.00103	CcSEcCtD
Imiquimod—Palpitations—Doxorubicin—bone cancer	6.06e-05	0.00102	CcSEcCtD
Imiquimod—Oedema—Epirubicin—bone cancer	6.05e-05	0.00102	CcSEcCtD
Imiquimod—Loss of consciousness—Doxorubicin—bone cancer	6.03e-05	0.00101	CcSEcCtD
Imiquimod—Infection—Epirubicin—bone cancer	6.01e-05	0.00101	CcSEcCtD
Imiquimod—Cough—Doxorubicin—bone cancer	5.99e-05	0.00101	CcSEcCtD
Imiquimod—Shock—Epirubicin—bone cancer	5.95e-05	0.001	CcSEcCtD
Imiquimod—Convulsion—Doxorubicin—bone cancer	5.95e-05	0.000999	CcSEcCtD
Imiquimod—Nervous system disorder—Epirubicin—bone cancer	5.94e-05	0.000997	CcSEcCtD
Imiquimod—Hypertension—Doxorubicin—bone cancer	5.92e-05	0.000995	CcSEcCtD
Imiquimod—Tachycardia—Epirubicin—bone cancer	5.91e-05	0.000992	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Methotrexate—bone cancer	5.89e-05	0.00099	CcSEcCtD
Imiquimod—Skin disorder—Epirubicin—bone cancer	5.88e-05	0.000988	CcSEcCtD
Imiquimod—Hyperhidrosis—Epirubicin—bone cancer	5.85e-05	0.000983	CcSEcCtD
Imiquimod—Insomnia—Methotrexate—bone cancer	5.85e-05	0.000983	CcSEcCtD
Imiquimod—Myalgia—Doxorubicin—bone cancer	5.84e-05	0.000981	CcSEcCtD
Imiquimod—Chest pain—Doxorubicin—bone cancer	5.84e-05	0.000981	CcSEcCtD
Imiquimod—Arthralgia—Doxorubicin—bone cancer	5.84e-05	0.000981	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—JUN—bone cancer	5.83e-05	0.00455	CbGpPWpGaD
Imiquimod—Anxiety—Doxorubicin—bone cancer	5.82e-05	0.000978	CcSEcCtD
Imiquimod—Paraesthesia—Methotrexate—bone cancer	5.81e-05	0.000976	CcSEcCtD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	5.8e-05	0.000975	CcSEcCtD
Imiquimod—Discomfort—Doxorubicin—bone cancer	5.77e-05	0.00097	CcSEcCtD
Imiquimod—Anorexia—Epirubicin—bone cancer	5.77e-05	0.000969	CcSEcCtD
Imiquimod—Dyspnoea—Methotrexate—bone cancer	5.77e-05	0.000969	CcSEcCtD
Imiquimod—Somnolence—Methotrexate—bone cancer	5.75e-05	0.000966	CcSEcCtD
Imiquimod—Dry mouth—Doxorubicin—bone cancer	5.71e-05	0.00096	CcSEcCtD
Imiquimod—Dyspepsia—Methotrexate—bone cancer	5.69e-05	0.000956	CcSEcCtD
Imiquimod—Decreased appetite—Methotrexate—bone cancer	5.62e-05	0.000945	CcSEcCtD
Imiquimod—Oedema—Doxorubicin—bone cancer	5.6e-05	0.000941	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Methotrexate—bone cancer	5.58e-05	0.000938	CcSEcCtD
Imiquimod—Fatigue—Methotrexate—bone cancer	5.58e-05	0.000937	CcSEcCtD
Imiquimod—Infection—Doxorubicin—bone cancer	5.56e-05	0.000935	CcSEcCtD
Imiquimod—Pain—Methotrexate—bone cancer	5.53e-05	0.000929	CcSEcCtD
Imiquimod—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	5.53e-05	0.00431	CbGpPWpGaD
Imiquimod—Musculoskeletal discomfort—Epirubicin—bone cancer	5.51e-05	0.000926	CcSEcCtD
Imiquimod—Shock—Doxorubicin—bone cancer	5.51e-05	0.000926	CcSEcCtD
Imiquimod—Nervous system disorder—Doxorubicin—bone cancer	5.49e-05	0.000923	CcSEcCtD
Imiquimod—Insomnia—Epirubicin—bone cancer	5.47e-05	0.00092	CcSEcCtD
Imiquimod—Tachycardia—Doxorubicin—bone cancer	5.47e-05	0.000918	CcSEcCtD
Imiquimod—Skin disorder—Doxorubicin—bone cancer	5.44e-05	0.000914	CcSEcCtD
Imiquimod—Paraesthesia—Epirubicin—bone cancer	5.43e-05	0.000913	CcSEcCtD
Imiquimod—Hyperhidrosis—Doxorubicin—bone cancer	5.41e-05	0.00091	CcSEcCtD
Imiquimod—Dyspnoea—Epirubicin—bone cancer	5.4e-05	0.000907	CcSEcCtD
Imiquimod—Somnolence—Epirubicin—bone cancer	5.38e-05	0.000904	CcSEcCtD
Imiquimod—Anorexia—Doxorubicin—bone cancer	5.34e-05	0.000897	CcSEcCtD
Imiquimod—Feeling abnormal—Methotrexate—bone cancer	5.33e-05	0.000895	CcSEcCtD
Imiquimod—Dyspepsia—Epirubicin—bone cancer	5.33e-05	0.000895	CcSEcCtD
Imiquimod—Gastrointestinal pain—Methotrexate—bone cancer	5.29e-05	0.000889	CcSEcCtD
Imiquimod—Decreased appetite—Epirubicin—bone cancer	5.26e-05	0.000884	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Epirubicin—bone cancer	5.23e-05	0.000878	CcSEcCtD
Imiquimod—Fatigue—Epirubicin—bone cancer	5.22e-05	0.000877	CcSEcCtD
Imiquimod—Pain—Epirubicin—bone cancer	5.18e-05	0.00087	CcSEcCtD
Imiquimod—Urticaria—Methotrexate—bone cancer	5.14e-05	0.000863	CcSEcCtD
Imiquimod—Abdominal pain—Methotrexate—bone cancer	5.11e-05	0.000859	CcSEcCtD
Imiquimod—Body temperature increased—Methotrexate—bone cancer	5.11e-05	0.000859	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Doxorubicin—bone cancer	5.1e-05	0.000857	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—MDM2—bone cancer	5.09e-05	0.00397	CbGpPWpGaD
Imiquimod—Insomnia—Doxorubicin—bone cancer	5.07e-05	0.000851	CcSEcCtD
Imiquimod—Paraesthesia—Doxorubicin—bone cancer	5.03e-05	0.000845	CcSEcCtD
Imiquimod—Dyspnoea—Doxorubicin—bone cancer	4.99e-05	0.000839	CcSEcCtD
Imiquimod—Feeling abnormal—Epirubicin—bone cancer	4.99e-05	0.000838	CcSEcCtD
Imiquimod—Somnolence—Doxorubicin—bone cancer	4.98e-05	0.000836	CcSEcCtD
Imiquimod—TLR8—Immune System—KIT—bone cancer	4.96e-05	0.00387	CbGpPWpGaD
Imiquimod—Gastrointestinal pain—Epirubicin—bone cancer	4.95e-05	0.000832	CcSEcCtD
Imiquimod—Dyspepsia—Doxorubicin—bone cancer	4.93e-05	0.000828	CcSEcCtD
Imiquimod—Decreased appetite—Doxorubicin—bone cancer	4.87e-05	0.000818	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Doxorubicin—bone cancer	4.83e-05	0.000812	CcSEcCtD
Imiquimod—Fatigue—Doxorubicin—bone cancer	4.83e-05	0.000811	CcSEcCtD
Imiquimod—Urticaria—Epirubicin—bone cancer	4.81e-05	0.000808	CcSEcCtD
Imiquimod—Pain—Doxorubicin—bone cancer	4.79e-05	0.000805	CcSEcCtD
Imiquimod—Body temperature increased—Epirubicin—bone cancer	4.78e-05	0.000804	CcSEcCtD
Imiquimod—Abdominal pain—Epirubicin—bone cancer	4.78e-05	0.000804	CcSEcCtD
Imiquimod—Hypersensitivity—Methotrexate—bone cancer	4.77e-05	0.000801	CcSEcCtD
Imiquimod—Asthenia—Methotrexate—bone cancer	4.64e-05	0.00078	CcSEcCtD
Imiquimod—Feeling abnormal—Doxorubicin—bone cancer	4.61e-05	0.000775	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—EGFR—bone cancer	4.59e-05	0.00358	CbGpPWpGaD
Imiquimod—Gastrointestinal pain—Doxorubicin—bone cancer	4.58e-05	0.000769	CcSEcCtD
Imiquimod—Pruritus—Methotrexate—bone cancer	4.58e-05	0.000769	CcSEcCtD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	4.54e-05	0.00355	CbGpPWpGaD
Imiquimod—Hypersensitivity—Epirubicin—bone cancer	4.46e-05	0.000749	CcSEcCtD
Imiquimod—Urticaria—Doxorubicin—bone cancer	4.45e-05	0.000747	CcSEcCtD
Imiquimod—Body temperature increased—Doxorubicin—bone cancer	4.43e-05	0.000744	CcSEcCtD
Imiquimod—Abdominal pain—Doxorubicin—bone cancer	4.43e-05	0.000744	CcSEcCtD
Imiquimod—Diarrhoea—Methotrexate—bone cancer	4.43e-05	0.000743	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—JUN—bone cancer	4.42e-05	0.00345	CbGpPWpGaD
Imiquimod—Asthenia—Epirubicin—bone cancer	4.34e-05	0.00073	CcSEcCtD
Imiquimod—CYP1A2—Phase II conjugation—GSTP1—bone cancer	4.29e-05	0.00335	CbGpPWpGaD
Imiquimod—Pruritus—Epirubicin—bone cancer	4.28e-05	0.000719	CcSEcCtD
Imiquimod—Dizziness—Methotrexate—bone cancer	4.28e-05	0.000719	CcSEcCtD
Imiquimod—Diarrhoea—Epirubicin—bone cancer	4.14e-05	0.000696	CcSEcCtD
Imiquimod—Hypersensitivity—Doxorubicin—bone cancer	4.13e-05	0.000693	CcSEcCtD
Imiquimod—Vomiting—Methotrexate—bone cancer	4.11e-05	0.000691	CcSEcCtD
Imiquimod—Rash—Methotrexate—bone cancer	4.08e-05	0.000685	CcSEcCtD
Imiquimod—Dermatitis—Methotrexate—bone cancer	4.07e-05	0.000684	CcSEcCtD
Imiquimod—Headache—Methotrexate—bone cancer	4.05e-05	0.000681	CcSEcCtD
Imiquimod—Asthenia—Doxorubicin—bone cancer	4.02e-05	0.000675	CcSEcCtD
Imiquimod—Dizziness—Epirubicin—bone cancer	4e-05	0.000672	CcSEcCtD
Imiquimod—Pruritus—Doxorubicin—bone cancer	3.96e-05	0.000666	CcSEcCtD
Imiquimod—TLR8—Immune System—MDM2—bone cancer	3.91e-05	0.00305	CbGpPWpGaD
Imiquimod—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	3.87e-05	0.00302	CbGpPWpGaD
Imiquimod—Vomiting—Epirubicin—bone cancer	3.85e-05	0.000647	CcSEcCtD
Imiquimod—Nausea—Methotrexate—bone cancer	3.84e-05	0.000645	CcSEcCtD
Imiquimod—Diarrhoea—Doxorubicin—bone cancer	3.83e-05	0.000644	CcSEcCtD
Imiquimod—Rash—Epirubicin—bone cancer	3.82e-05	0.000641	CcSEcCtD
Imiquimod—Dermatitis—Epirubicin—bone cancer	3.81e-05	0.000641	CcSEcCtD
Imiquimod—Headache—Epirubicin—bone cancer	3.79e-05	0.000637	CcSEcCtD
Imiquimod—TLR7—Immune System—KIT—bone cancer	3.76e-05	0.00293	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	3.74e-05	0.00291	CbGpPWpGaD
Imiquimod—Dizziness—Doxorubicin—bone cancer	3.7e-05	0.000622	CcSEcCtD
Imiquimod—Nausea—Epirubicin—bone cancer	3.6e-05	0.000604	CcSEcCtD
Imiquimod—Vomiting—Doxorubicin—bone cancer	3.56e-05	0.000598	CcSEcCtD
Imiquimod—Rash—Doxorubicin—bone cancer	3.53e-05	0.000593	CcSEcCtD
Imiquimod—Dermatitis—Doxorubicin—bone cancer	3.53e-05	0.000593	CcSEcCtD
Imiquimod—Headache—Doxorubicin—bone cancer	3.51e-05	0.000589	CcSEcCtD
Imiquimod—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	3.49e-05	0.00273	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—EGFR—bone cancer	3.48e-05	0.00271	CbGpPWpGaD
Imiquimod—TLR8—Immune System—JUN—bone cancer	3.4e-05	0.00265	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	3.37e-05	0.00263	CbGpPWpGaD
Imiquimod—Nausea—Doxorubicin—bone cancer	3.33e-05	0.000559	CcSEcCtD
Imiquimod—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	2.99e-05	0.00233	CbGpPWpGaD
Imiquimod—TLR7—Immune System—MDM2—bone cancer	2.96e-05	0.00231	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—CYP3A4—bone cancer	2.94e-05	0.00229	CbGpPWpGaD
Imiquimod—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	2.89e-05	0.00226	CbGpPWpGaD
Imiquimod—TLR8—Immune System—EGFR—bone cancer	2.67e-05	0.00208	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	2.65e-05	0.00207	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	2.65e-05	0.00207	CbGpPWpGaD
Imiquimod—TLR7—Immune System—JUN—bone cancer	2.57e-05	0.00201	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—GSTP1—bone cancer	2.51e-05	0.00196	CbGpPWpGaD
Imiquimod—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	2.48e-05	0.00193	CbGpPWpGaD
Imiquimod—TLR7—Immune System—EGFR—bone cancer	2.02e-05	0.00158	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—GSTP1—bone cancer	1.94e-05	0.00151	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	1.91e-05	0.00149	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—NDUFA12—bone cancer	1.76e-05	0.00137	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—NT5C3A—bone cancer	1.46e-05	0.00114	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—NDUFA12—bone cancer	1.36e-05	0.00106	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—NT5C3A—bone cancer	1.13e-05	0.000878	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ENO2—bone cancer	6.39e-06	0.000498	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—DHFR—bone cancer	5.92e-06	0.000462	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GNA11—bone cancer	5.54e-06	0.000432	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CYP3A4—bone cancer	5.02e-06	0.000392	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.99e-06	0.00039	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ENO2—bone cancer	4.93e-06	0.000385	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—DHFR—bone cancer	4.57e-06	0.000357	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GSTP1—bone cancer	4.29e-06	0.000335	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GNA11—bone cancer	4.27e-06	0.000333	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GSTP1—bone cancer	3.31e-06	0.000259	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PTGS2—bone cancer	2.22e-06	0.000174	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PTGS2—bone cancer	1.72e-06	0.000134	CbGpPWpGaD
